Netherlands Cancer Institute

The Netherlands Cancer Institute (NKI) is a Comprehensive Cancer Center in The Netherlands (Amsterdam). It is a well-organized and dynamic cancer research institute accommodating over 50 research groups and advanced core facilities. It is an internationally renowned center covering fundamental, translational and clinical cancer research.

The department of Radiology, chaired by Professor Regina Beets-Tan, pursues research in oncological imaging covering a broad spectrum of cancer types. The most established line of research within the group is MR imaging of rectal carcinoma – resulting so far in over ten doctoral theses, 97 high-impact publications and numerous contributions to international congresses. The research output has served as the basis for several international guidelines in the area of colorectal carcinoma.

In recent years, the department has focused research efforts on developing AI models in oncological imaging, covering topics such as patient and treatment monitoring, radiogenomics, and response or recurrence. The Beets-Tan group is also actively invested in researching novel AI techniques to tackle the inherent difficulties of multi-center data and explainable AI.

Role of institution in the project

The Beets-Tan group has experience in the procuration of international multi-center datasets for radiomics and deep learning analyses, by being involved in the EU H2020 CAST project, providing necessary experience to contribute to WP2 – Engagement and Liaison of Data Providers.

The group participated in an international federated learning collaboration to annotate brain tumors (across 146 centers). This included preparation of the internal approvals and software development. The group has an active research line related to AI for multi-center data with focus on federated learning, and privacy. This provides relevant expertise for WP6 – Federated data processing and analysis.

Regina Beets-Tan

Regina Beets-Tan is Chair of the Department of Radiology at the Netherlands Cancer Institute in Amsterdam, Netherlands. She is Professor of Radiology at the University of Maastricht, Netherlands and Adjunct Professor of Abdominal and Oncological Radiology at the University of Southern Denmark, Denmark. She obtained her MD, cum laude, at the Erasmus University Rotterdam, Netherlands, and her PhD thesis on rectal cancer MR imaging, which she obtained at the University of Maastricht, Netherlands, was awarded the 2001 Best Thesis Prize. Regina's main clinical interest has been abdominal and oncological imaging. She leads research in cancer imaging in the Netherlands Cancer Institute, focusing on the validation of multi parametric and artificial intelligence imaging technology as a guidance for interventional, surgical and radiation treatment, and as a biomarker for treatment efficacy in cancer. Her own research track record is in rectal cancer imaging for better treatment outcome, for which she collaborates with multidisciplinary expert teams worldwide, including the Memorial Sloan Kettering Cancer Center, USA where she was affiliated in 2008.

Wilson Silva

Wilson Silva is a Postdoctoral Fellow at the Department of Radiology at The Netherlands Cancer Institute. He has a MSc in Electrical and Computer Engineering and a PhD in Machine Learning and Medical Image Analysis, both obtained at the University of Porto, Portugal. Dr. Silva is currently leading a research line related to AI for multi-center data, focusing on generalizability, privacy and interpretability of AI in cancer research.

Zuhir Bodalal

Zuhir Bodalal is a clinician-scientist with a background in immuno-oncology, imaging, and artificial intelligence. Currently based at the Department of Radiology at the Netherlands Cancer Institute, he serves as a team lead within the AI Imaging Team. His research focuses on non-invasive exploration of tumor biology and micro-environment, using a variety of methods from molecular imaging, machine learning, and (big-)data science. Dr. Bodalal is a member of the Young Radiologists Committee of the European Society of Oncological Imaging and the Young ESGAR e-Education Committee. He sits at a round table with doctors, biologists, and engineers daily.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

SAVE THE DATE
March 14, 10:00-11:30 aM CET

DISCOVER THE CANCER IMAGE EUROPE PLATFORM

TECHNICAL DEMONSTRATION WEBINAR

Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.